Literature DB >> 19199922

Current status of newer carbapenems.

Matteo Bassetti1, Laura Nicolini, Silvano Esposito, Elda Righi, Claudio Viscoli.   

Abstract

OBJECTIVES: Beta-lactam antibiotics represent the most commonly prescribed antibacterial agents. Since many bacteria have developed resistance to older agents, new beta-lactams have been introduced constantly. In the late 1970s, a new class of exceptionally broad-spectrum beta-lactams, the carbapenems, was identified. The carbapenems, such as the most popular imipenem and meropenem, have the widest spectra of antibacterial activity of all the beta-lactams and provide excellent coverage of many gram-negative and gram-positive aerobic and anaerobic bacteria. Despite the wide antibacterial spectrum, the carbapenems globally lack activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA) and Stenotrophomonas maltophilia.
METHODS: We reviewed the principal characteristics of the novel carbapenems and their clinical implications. RESULTS AND
CONCLUSIONS: We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199922     DOI: 10.2174/092986709787458498

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  12 in total

1.  Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.

Authors:  Kazuro Ikawa; Akira Nakashima; Norifumi Morikawa; Kayo Ikeda; Yoshiaki Murakami; Hiroki Ohge; Hartmut Derendorf; Taijiro Sueda
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

Review 2.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

3.  Enantiomerically pure trans-beta-lactams from alpha-amino acids via compact fluorescent light (CFL) continuous-flow photolysis.

Authors:  Yvette S Mimieux Vaske; Maximillian E Mahoney; Joseph P Konopelski; David L Rogow; William J McDonald
Journal:  J Am Chem Soc       Date:  2010-08-18       Impact factor: 15.419

4.  Peptidoglycan Recycling Promotes Outer Membrane Integrity and Carbapenem Tolerance in Acinetobacter baumannii.

Authors:  Nowrosh Islam; Misha I Kazi; Katie N Kang; Jacob Biboy; Joe Gray; Feroz Ahmed; Richard D Schargel; Cara C Boutte; Tobias Dörr; Waldemar Vollmer; Joseph M Boll
Journal:  mBio       Date:  2022-05-31       Impact factor: 7.786

Review 5.  New antimicrobial strategies in cystic fibrosis.

Authors:  Mireille van Westreenen; Harm A W M Tiddens
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

6.  Discovery and characterization of New Delhi metallo-β-lactamase-1 inhibitor peptides that potentiate meropenem-dependent killing of carbapenemase-producing Enterobacteriaceae.

Authors:  Misha I Kazi; Blair W Perry; Daren C Card; Richard D Schargel; Hana B Ali; Victor C Obuekwe; Madhab Sapkota; Katie N Kang; Mark W Pellegrino; David E Greenberg; Todd A Castoe; Joseph M Boll
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

Review 7.  New treatment options against gram-negative organisms.

Authors:  Matteo Bassetti; Francesca Ginocchio; Malgorzata Mikulska
Journal:  Crit Care       Date:  2011-03-22       Impact factor: 9.097

8.  Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis.

Authors:  Saugata Hazra; Hua Xu; John S Blanchard
Journal:  Biochemistry       Date:  2014-05-29       Impact factor: 3.162

9.  Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial.

Authors:  Xiaohui Wang; Xiaoke Zhang; Zhiyong Zong; Rujia Yu; Xiaoju Lv; Jianbao Xin; Chaohui Tong; Qinglin Hao; Zhiqiang Qin; Ying Xiong; Hong Liu; Guohua Ding; Chengping Hu
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375

Review 10.  New antibiotics for bad bugs: where are we?

Authors:  Matteo Bassetti; Maria Merelli; Chiara Temperoni; Augusta Astilean
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-08-28       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.